GDC--0084, page-22

RBX

Good summary

IMO

Don't think $4m top up now or a $10m capital raising will erase market uncertainty when capital requirement estimates are well beyond those levels

Edison Valuations for full GDC0084 success and including Cantrixil have remained similar from 2016 up until last report 23/6/19

Cantrixil Phase 1 ????

GDC0084 phase 11b ?????


Edison Report 23/06/2019

We estimate that Kazia will need additional funds in the order of A$15–20m to fully fund the GDC-0084 Phase IIb study.

Valuation $84m- $135m


Edison report 31/10/2016

Our valuation of Novogen’s existing programme is unchanged at A$112m (A$0.26/share). pre consolidation value

We value GDC-0084 under two different scenarios at A$11-54m, after accounting for A$35m of anticipated clinical trial costs. phase 11a and phase 11b etc...


DYOR